Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
We tested three compounds for their ability to inhibit the RNase H (RH) and polymerase activities of HIV-1 reverse transcriptase (RT). A high-resolution crystal structure (2.2 Å) of one of the compounds showed that it chelates the two magnesium ions at the RH active site; this prevents the RH active site from interacting with, and cleaving, the RNA strand of an RNA-DNA heteroduplex. The compounds were tested using a variety of substrates: all three compounds inhibited the polymerase-independent RH activity of HIV-1 RT. Time-of-addition experiments showed that the compounds were more potent if they were bound to RT before the nucleic acid substrate was added. The compounds significantly inhibited the site-specific cleavage required to generate the polypurine tract (PPT) RNA primer that initiates the second strand of viral DNA synthesis. The compounds also reduced the polymerase activity of RT; this ability was a result of the compounds binding to the RH active site. These compounds appear to be relatively specific; they do not inhibit either Escherichia coli RNase HI or human RNase H2. The compounds inhibit the replication of an HIV-1-based vector in a one-round assay, and their potencies were only modestly decreased by mutations that confer resistance to integrase strand transfer inhibitors (INSTIs), nucleoside analogs, or nonnucleoside RT inhibitors (NNRTIs), suggesting that their ability to block HIV replication is related to their ability to block RH cleavage. These compounds appear to be useful leads that can be used to develop more potent and specific compounds. IMPORTANCE Despite advances in HIV-1 treatment, drug resistance is still a problem. Of the four enzymatic activities found in HIV-1 proteins (protease, RT polymerase, RT RNase H, and integrase), only RNase H has no approved therapeutics directed against it. This new target could be used to design and develop new classes of inhibitors that would suppress the replication of the drug-resistant variants that have been selected by the current therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNase H activity: structure, specificity, and function in reverse transcription
Schultz, S. J., & Champoux, J. J. (2008) · Virus Research · doi:10.1016/j.virusres.2007.12.007 · Cited by 150 · cited 3×
“It has also been suggested that this would allow the RH to cleave at multiple places within the nucleic acid substrate (13, 14, 19).”
BackgroundHIV-1 ribonuclease H: structure, catalytic mechanism and inhibitors
Beilhartz, G. L., & Götte, M. (2010) · Viruses · doi:10.3390/v2040900 · Cited by 88 · cited 1×
“secondary cleavages but have little or no effect on the primary cleavages (3, 4).”
BackgroundRibonuclease H: properties, substrate specificity and roles in retroviral reverse transcription
Champoux, J. J., & Schultz, S. J. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.06909.x · Cited by 77 · cited 2×
“It has also been suggested that this would allow the RH to cleave at multiple places within the nucleic acid substrate (13, 14, 19).”
BackgroundSchultz, S. J., Zhang, M., & Champoux, J. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510504200 · Cited by 35
Recent progress in the research of small molecule HIV-1 RNase H inhibitors
Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140120121158 · Cited by 34
Research works printed but not linked: 32
- 10.1016/j.jmb.2009.03.025 · DOI · Paper page
- 10.1021/jm900597q · DOI · Paper page
- 10.1074/jbc.M114.569707 · DOI · Paper page
- 10.1021/acs.jmedchem.7b00440 · DOI · Paper page
- 10.3389/fmicb.2017.00440 · DOI
- 10.1128/microbiolspec.MDNA3-0027-2014 · DOI · Paper page
- 10.1021/jm5001908 · DOI
- 10.1021/jm040840e · DOI · Paper page
- 10.1073/pnas.0711209105 · DOI · Paper page
- 10.1128/JVI.00353-10 · DOI · Paper page
- 10.1074/jbc.M507839200 · DOI
- 10.1074/jbc.M201645200 · DOI · Paper page
- 10.1128/JVI.78.12.6112-6121.2004 · DOI
- 10.1016/j.jmb.2004.09.081 · DOI
- 10.1111/j.1742-4658.2009.06908.x · DOI · Paper page
- 10.1128/JVI.75.2.672-686.2001 · DOI
- 10.1074/jbc.M700043200 · DOI
- 10.1074/jbc.M116.753160 · DOI
- 10.1016/j.str.2009.09.016 · DOI · Paper page
- 10.1016/j.jmb.2014.05.006 · DOI · Paper page
- 10.1021/jm070715d · DOI
- 10.1016/j.bmcl.2010.08.135 · DOI
- 10.1021/jm00395a015 · doi:10.1021/jm00395a015
- 10.1128/JVI.02611-06 · DOI
- 10.3791/51400 · DOI
- 10.1021/jm401902n · DOI
- 10.1021/acschembio.5b00948 · DOI · Paper page
- 10.1097/QAI.0000000000001031 · DOI · Paper page
- 10.1093/nar/gkn464 · DOI · Paper page
- 10.1107/S0907444910048675 · DOI · Paper page
- 10.1107/S0907444909052925 · DOI · Paper page
- 10.1107/S0907444904019158 · DOI · Paper page
Cited by
Wang, L., Sarafianos, S. G., & Wang, Z. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00450 · Cited by 43
Corona, A., Onnis, V., Del Vecchio, C., Esposito, F., Cheng, Y.-C., & Tramontano, E. (2020) · Molecules · doi:10.3390/molecules25061338 · Cited by 19
“The RNase H active-site inhibitors take advantage of the driving force represented by their chelating moiety to stably interact with the catalytic domain [21,22]; however, their development is often hampered by off-target toxicity and competition with nucleic acid substrates [23,24], and by the difficulties to establi…”
BackgroundRetroviral RNase H: structure, mechanism, and inhibition
(2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.007 · Cited by 13
Metadata
- Authors
- Boyer, P. L., Smith, S. J., Zhao, X. Z., Das, K., Gruber, K., Arnold, E., Burke, T. R., & Hughes, S. H.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2018-07
- Volume
- 92
- Issue
- 13
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W2808340159
- Cited by
- 38
- References
- 5
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase. https://app.cochat.ai/papers/10.1128/jvi.02203-17
- The paper
- Boyer, P. L., Smith, S. J., Zhao, X. Z., Das, K., Gruber, K., Arnold, E., Burke, T. R., & Hughes, S. H. (2018). Developing and Evaluating Inhibitors against the RNase H Active Site of HIV-1 Reverse Transcriptase. Journal of Virology. https://doi.org/10.1128/jvi.02203-17
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.